Multiple sclerosis (MS)
254 results
158 - 254
Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis- Mycophenolate mofetil for relapsing-remitting multiple sclerosis: Cochrane systematic review
Alemtuzumab for multiple sclerosis - Non-pharmacological interventions for spasticity in multiple sclerosis
- Daclizumab for relapsing remitting multiple sclerosis
- Mitoxantrone for multiple sclerosis: Cochrane systematic review
- Natalizumab for relapsing remitting multiple sclerosis: Cochrane systematic review
- Glatiramer acetate for multiple sclerosis
- Glatiramer acetate for multiple sclerosis
- Obstipation in the adult
- Rituximab for people with multiple sclerosis
- Multidisciplinary rehabilitation for adults with multiple sclerosis
- Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
- Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
- Interferon beta for secondary progressive multiple sclerosis
- Rituximab for relapsing-remitting multiple sclerosis: Cochrane systematic review
- Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews
- Vitamin D for the management of multiple sclerosis
- Non pharmacological interventions for spasticity in multiple sclerosis: Cochrane systematic review
- Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
- Corticosteroids for the long-term treatment in multiple sclerosis
- Teriflunomide for multiple sclerosis
- Memory rehabilitation for people with multiple sclerosis
- Interferons‐beta versus glatiramer acetate for relapsing‐remitting multiple sclerosis
- Corticosteroids or ACTH for acute exacerbations in multiple sclerosis: Cochrane systematic review
- Respiratory muscle training for multiple sclerosis
- Multidisciplinary rehabilitation for adults with multiple sclerosis
- Siponimod for multiple sclerosis
- Dyspnoea
- Alemtuzumab for multiple sclerosis
- Diseases of the spinal cord
- Cyclophosphamide for multiple sclerosis
- Dimethyl fumarate for multiple sclerosis: Cochrane systematic review
- Neuropsychological rehabilitation for multiple sclerosis
- Pharmacologic treatment for memory disorder in multiple sclerosis
- Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis
- Dietary interventions for multiple sclerosis‐related outcomes
- Eye symptoms and signs of systemic diseases
- Fatigue
OB outcomes for those with MS and epilepsy similar to general population; diabetics worse- Interventions for preventing falls in people with multiple sclerosis
- Memory rehabilitation in multiple sclerosis
- Telerehabilitation for persons with multiple sclerosis
- Virtual reality for multiple sclerosis rehabilitation
- Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
- Lumbar spinal stenosis (LSS)
- Burning mouth and glossalgia
- Adverse effects of immunotherapies for multiple sclerosis: a network meta‐analysis
- Benign paroxysmal positional vertigo (BPPV)
- Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis
- Exercise therapy for fatigue in multiple sclerosis
- Interferon in relapsing‐remitting multiple sclerosis
- Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis
- Cholinesterase inhibitors for rarer dementias associated with neurological conditions: Cochrane systematic review
- Ocrelizumab for multiple sclerosis
- Ataxia
- Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis
- Neuropsychological rehabilitation for multiple sclerosis: Cochrane systematic review
- Immunomodulators and immunosuppressants for progressive multiple sclerosis: a network meta‐analysis
- Treatment with disease‐modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
- Natalizumab for multiple sclerosis
- alemtuzumab versus interferon beta 1a for relapsing‐remitting multiple sclerosis
- Psychological interventions for multiple sclerosis
- Raynaud's phenomenon (RP) or white finger disease
- Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis (RRMS): a network meta-analysis
- Fingolimod for relapsing‐remitting multiple sclerosis
- Medical marijuana for various neurologic conditions: mixed outcomes
- Muscle weakness and paralysis symptom
- Gait disturbances
- Primary Sjögren's syndrome
- Vertigo
- Corticosteroids for treating optic neuritis
- Pharmacological treatments for fatigue associated with palliative care: Cochrane systematic review
- Pruritus
- Effectiveness and cost‐effectiveness of home palliative care services for adults with advanced illness and their caregivers
- Surgical management of functional bladder outlet obstruction in adults with neurogenic bladder dysfunction
- Trigeminal neuralgia and other facial pain
- Lyme borreliosis (LB)